News Related to Icahn School of Medicine at Mount Sinai

Related coverage linked through entity extraction aliases.

Subcutaneous Infliximab Recaptures Disease Control After Treatment Interruption

Feb 16, 2026

New data from LIBERTY studies show subcutaneous infliximab effectively restored and maintained disease control in Crohn's disease and ulcerative colitis patients after drug holiday of 16 weeks or more, with sustained efficacy through Week 102.

Depression Shares Immune Signature with Atopic Dermatitis, Study Finds

Feb 13, 2026

Researchers at Icahn School of Medicine at Mount Sinai found that major depressive disorder shares key immune abnormalities with atopic dermatitis, particularly Th2 pathway activation. The team plans to test dupilumab in a clinical trial for depression.